Treatment of Pancreatic Cancer With Abraxane

Status Completed

Clinical Trial Summary

This observational program collects data on tolerability, safety and efficacy regarding the use of Abraxane in metastatic pancreatic cancer patients in the daily clinical routine. Additionally data on dosage that is actually used in these patients will be collected. Patients who have pancreatic cancer and additional diseases can be documented in this study, too. Collected data might generate learnings on the optimal use of Abraxane in the daily routine setting.

Clinical Trial Description

This observational program is aimed at gaining tolerability, safety and efficacy data with the routine use of Abraxane in its labeled indication in metastatic pancreatic cancer. Additionally data on real life dosing in daily clinical routine will be analyzed. A detailed record of the medical history including co-morbidities and pre-treatment regimens will allow analysis of the impact thereof on tolerability, dosage and efficacy. Hands-on experience with nab-paclitaxel is very limited in Austria and an non-interventional study could enhance knowledge on optimal drug handling and Adverse Event management. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02555813
Study type	Observational
Source	Celgene
Contact
Status	Completed
Phase
Start date	May 8, 2015
Completion date	September 7, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04753879` - Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.	Phase 2
Completed	`NCT01417000` - Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer	Phase 2
Active, not recruiting	`NCT02975141` - Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer	Phase 1
Active, not recruiting	`NCT00761345` - Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer	Phase 1
Completed	`NCT00919282` - Gemcitabine (GFF) in Patients With Pancreatic Cancer	Phase 2
Completed	`NCT01088815` - Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas	Phase 2
Completed	`NCT04133155` - Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
Withdrawn	`NCT05251038` - Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer	Phase 1/Phase 2
Recruiting	`NCT04612530` - PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer	Phase 1
Completed	`NCT03602885` - EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options	N/A
Recruiting	`NCT05442749` - Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer	Phase 2
Recruiting	`NCT04222413` - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors	Phase 1
Recruiting	`NCT03721744` - A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer	Phase 2/Phase 3
Completed	`NCT03261947` - A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors	Phase 2
Withdrawn	`NCT06017323` - Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1
Terminated	`NCT01946646` - Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer	Phase 1
Completed	`NCT01523457` - Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer	Phase 2
Active, not recruiting	`NCT00986661` - A Study to Assess PV-10 Chemoablation of Cancer of the Liver	Phase 1
Terminated	`NCT00726037` - A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT00744640` - Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma	Phase 1/Phase 2